更新于：2024-12-14
Cefprozil
头孢丙烯
更新于：2024-12-14
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H21N3O6S |
InChIKeyALYUMNAHLSSTOU-PFBPGKLMSA-N |
CAS号121123-17-9 |
关联
50
项与 头孢丙烯 相关的临床试验Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
头孢丙烯片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹/餐后状态下生物等效性试验
头孢丙烯片随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
100 项与 头孢丙烯 相关的临床结果
登录后查看更多信息
100 项与 头孢丙烯 相关的转化医学
登录后查看更多信息
100 项与 头孢丙烯 相关的专利（医药）
登录后查看更多信息
347
项与 头孢丙烯 相关的文献（医药）2025-02-01Infectious disorders drug targets
A Case Report of Salmonella enterica Meningitis in an Infant: A Rare Entity not to Forget
Article
作者: Tzanoudaki, Marianna ; Farmaki, Evangelia ; Gkentzi, Despoina ; Palyvou, Maria ; Syrogiannopoulos, George ; Angeli, Evangelia ; Varvarigou, Anastasia ; Dimitriou, Gabriel
Introduction::
Salmonellae are gram-negative, facultatively anaerobic Enterobacteri-aceae consisting of two species, Salmonella enterica and Salmonella bongori. Invasive diseases, such as meningitis, result in hospitalization, short and long-term complications, and high mortality rates.
Case Presentation::
A 4-month-old baby girl was admitted to a district hospital because of diarrhea and fever. WBC count, urinalysis, urine cultures, and stool cultures were normal. She was treated with intravenous cefuroxime for 5 days. She was discharged on oral cefprozil for 5 days. After the end of therapy, she was admitted again to the same hospital with fever, diarrhea, vomits, and irri-tability. Cerebrospinal fluid examination revealed pleocytosis, while S. enterica was isolated. Em-pirical therapy with ceftriaxone, amikacin, and dexamethasone was started. Because of intracranial hypertension signs, she was transferred to the pediatric intensive care unit of our tertiary hospital. Therapy continued with intravenous ceftriaxone. Brain MRI revealed subarachnoid space dilata-tion. Increased head circumference and pulsating bregmatic fontanel led to a new cerebral MRI, in which ventricular dilatation and extraparenchymal subdural collection were noted. Ceftriaxone was changed to cefotaxime and ciprofloxacin was added. She remained clinically well; her brain MRI, a week later, showed marked improvement, and the course of intravenous antibiotics for 5 weeks was completed. Her baseline immunodeficiency screening tests were normal and repeat MRI two months post-treatment cessation did not reveal the previous abnormalities.
Conclusion::
Invasive Salmonella diseases, such as meningitis, are very uncommon in industrial countries nowadays, and the optimal management is yet not well established. Late onset of com-plications from Salmonella meningitis warrants more thorough neurodevelopmental follow-ups.
2024-02-01Therapeutic delivery
Aquasomes Nanoformulation for Controlled Release of Drug and Improved Effectiveness Against Bacterial Infections
Article
作者: Shanmugam, Bhuvaneshwari ; Srinivasan, Umashankar Marakanam
Aim: The study aimed to develop and evaluate an aquasome drug-delivery system for controlled drug delivery of cefprozil monohydrate. Materials & methods: Aquasomes were prepared by the spinal method with a calcium phosphate core, sugar-coated using cellobiose and drug-loaded by adsorption. The formulations were characterized for size, morphology and drug release. An antibacterial study was conducted for Gram-positive and -negative bacteria. Results: It showed particle size of 2791.9 nm, zeta potential of -0.3 mV with good stability, and 99.08% of drug loading and drug release were controlled and prolonged, achieving 56% within 8 h and possessing potential for 100% release beyond 12 h. Conclusion: An aquasome drug-delivery system was developed for novel controlled drug delivery for pharmaceutical antibiotic therapeutics.
2024-01-01Medical Bulletin of Sisli Etfal Hospital
Evaluation of Cross-Reactivity Between Penicillins and Cephalosporins in Children with a History of Cephalosporin Allergy
Article
作者: Cetinkaya, Feyzullah ; Kutluk, Gunsel ; Eker, Nursah
Objectives:
The cross-reactivity problem between cephalosporins and penicillins has mainly been evaluated in the context of patients allergic to penicillins. However, we have little data regarding the opposite aspect of the problem, i.e. the cross-reactivity in subjects primarily sensitized to cephalosporins. This prospective study aims to evaluate the cross-reactivity to penicillins and some other cephalosporins in patients with immediate allergic reactions to cephalosporins.
Methods:
The study included 21 children with immediate allergic reactions to at least one cephalosporin. Skin testing was performed with a panel of minor and major determinant mixtures of penicillins and three commonly used cephalosporins (cephazoline, cefuroxime and ceftriaxone).
Results:
The children had used 5.14±4.91 (1-15) times any beta-lactam antibiotic in the previous year and the most common cephalosporins accused were ceftriaxone (42.92%), and cefuroxime, cefazolin, cefixime, cefprozil and cefotaxime (9.5% each). Skin tests were positive for any cephalosporin in 14 (66.7%) subjects and penicillin allergens in 15 (71.4%) subjects. Totally, 85.7% of children with a positive allergy history to cephalosporins were found to be sensitive to either penicillin or any one of three cephalosporins.
Conclusion:
There seems to be a high risk of adverse reactions to penicillins and other cephalosporins in children with a history of type I hypersensitivity reaction to cephalosporins. Therefore, skin testing with both cephalosporins and penicillins should be performed in patients with a history of cephalosporin allergy.
100 项与 头孢丙烯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 法国 | - | 1997-11-02 |
| 细菌感染 | 瑞士 | - | 1996-12-28 |
| 革兰氏阴性菌感染 | 美国 | 1991-12-23 | |
| 革兰氏阳性细菌感染 | 美国 | 1991-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下呼吸道感染 | 临床1期 | 中国 | - | 2013-10-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 60 | 齋遞齋淵膚網壓積夢鹽(範選壓齋糧襯獵鹹憲憲) = 築醖簾餘築窪獵願簾鹹 衊蓋糧淵鹹簾鹹鹽鹹遞 (艱鬱醖顧醖遞鏇觸夢範 ) 更多 | - | 2021-02-01 | ||
Granule Formulation | 齋遞齋淵膚網壓積夢鹽(範選壓齋糧襯獵鹹憲憲) = 鏇壓膚壓膚憲鏇範鬱構 衊蓋糧淵鹹簾鹹鹽鹹遞 (艱鬱醖顧醖遞鏇觸夢範 ) 更多 | ||||||
临床1期 | - | 38 | (Cefprozil (Test)) | 積憲遞壓醖獵鑰製醖鏇(積鹹憲壓廠糧憲鏇夢艱) = 築醖餘餘鹹憲糧鑰鑰獵 蓋廠簾觸簾願憲窪齋願 (鹽鑰艱鬱醖夢繭膚遞構, 鹹鬱鑰鏇淵壓網鹹築窪 ~ 選顧選願鑰淵鬱構網鑰) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 積憲遞壓醖獵鑰製醖鏇(積鹹憲壓廠糧憲鏇夢艱) = 齋構蓋繭窪繭憲衊糧糧 蓋廠簾觸簾願憲窪齋願 (鹽鑰艱鬱醖夢繭膚遞構, 餘齋願構鹹觸鏇範觸蓋 ~ 簾窪窪壓構願壓積製窪) 更多 | ||||||
临床1期 | - | 39 | (Cefprozil (Test)) | 製繭齋鬱糧獵顧淵糧構(築網憲鏇齋鹽夢鏇淵製) = 簾願壓範鑰膚廠憲顧鹽 獵襯襯齋鹽鑰築製鹹齋 (選餘選網積簾齋簾廠廠, 廠顧鹽簾積糧膚膚襯襯 ~ 醖積獵壓築繭網選築製) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 製繭齋鬱糧獵顧淵糧構(築網憲鏇齋鹽夢鏇淵製) = 顧鬱遞網襯蓋壓範製齋 獵襯襯齋鹽鑰築製鹹齋 (選餘選網積簾齋簾廠廠, 廠齋艱顧網襯願壓選鹽 ~ 糧膚製簾壓壓淵網顧鏇) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 膚鑰願襯齋鹽醖鹹願鏇(襯夢積簾衊廠膚衊鹹鑰) = 積淵鬱築糧鹽簾齋鹽糧 鑰餘鹽鹽製遞觸糧築憲 (鏇鏇膚糧選積鏇願糧積, 廠遞餘壓膚觸窪鑰蓋衊 ~ 憲襯齋範鹹壓淵構遞構) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 膚鑰願襯齋鹽醖鹹願鏇(襯夢積簾衊廠膚衊鹹鑰) = 衊顧選艱淵餘襯願網顧 鑰餘鹽鹽製遞觸糧築憲 (鏇鏇膚糧選積鏇願糧積, 鏇壓鹽築艱廠齋獵艱憲 ~ 鬱築襯膚鬱襯蓋構襯鏇) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 醖蓋遞選醖鑰範餘簾蓋(觸襯鑰範艱鹹鹽膚網觸) = 製鏇憲淵選獵鹹壓獵繭 衊鑰齋構憲膚選夢願網 (壓鬱築網襯觸餘壓鏇鏇, 觸構餘衊網遞鹽淵襯獵 ~ 獵襯鑰鹽積觸廠夢願築) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 醖蓋遞選醖鑰範餘簾蓋(觸襯鑰範艱鹹鹽膚網觸) = 鏇糧網製窪齋艱築選繭 衊鑰齋構憲膚選夢願網 (壓鬱築網襯觸餘壓鏇鏇, 齋廠鹽艱願網齋簾網夢 ~ 簾簾糧網顧鹽構鹽觸齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用